Repligen (RGEN) released its third quarter results, revealing year-over-year growth in both revenue and net income. The company shifted from last year’s net loss into positive territory and also ...
Repligen stands out as a leading bioprocess supplier, benefiting from secular growth in biologics and industry patent expirations. RGEN's strong balance sheet, recurring organic growth, and strategic ...
A number of stocks jumped in the afternoon session after the market experienced a sharp sector rotation, as investors fled growth-oriented technology stocks and piled into value-oriented names amid ...
Repligen erzielte ein organisches Wachstum von 18 %, während die Auftragseingänge um über 20 % stiegen. Das Unternehmen konzentriert sich auf den Ausbau seines kommerziellen Umsatzmixes, wobei ...
All right. With that, we're ready to kick things off. Next up, we have Repligen. Representing the company are Jason Garland and Jacob Johnson. Welcome, both of you. Yes. No, we were really happy with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback